LLY - Eli Lilly and Company
| Previous Close | 116.73 |
| Open | 115.70 |
| Bid | 116.18 x 900 |
| Ask | 116.19 x 800 |
| Day's Range | 115.22 - 116.65 |
| 52 Week Range | 81.61 - 132.13 |
| Volume | 2,970,961 |
| Avg. Volume | 16,116,407 |
| Market Cap | 106.826B |
| Beta (3Y Monthly) | 0.44 |
| PE Ratio (TTM) | 18.85 |
| EPS (TTM) | 6.16 |
| Earnings Date | Jul 30, 2019 |
| Forward Dividend & Yield | 2.58 (2.20%) |
| Ex-Dividend Date | 2019-05-16 |
| 1y Target Est | 124.57 |
- Yahoo Finance Video•10 days ago
Why this former health care CEO thinks this Uber board member is crucial to its success
Yahoo Finance's Alexis Christoforous and Brian Sozzi talk to former Aetna CEO and friend of Uber board member Ursula Burns about the current state of healthcare, the anticipation ahead of the Uber IPO and overall stocks that are gaining attention in the market.
- CNBC Videos•15 days ago
Migraine drugs cause pain for investors
CNBC's Meg Tirrell reports on a group of migraine drug manufacturers that missed expectations on earnings.
- Benzinga•17 hours ago
The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Readouts And IPOs
Biotech stocks came under pressure this week along with the broader market, which succumbed to the negative sentiment generated by U.S.-China trade tensions. However, they recouped some of these losses, ...
- Zacks•2 days ago
Pharma Stock Roundup: FDA Okays Line Extensions of LLY, PFE, ABBV Cancer Drugs
FDA grants approval for line extensions of Lilly (LLY), Pfizer (PFE) and Roche (RHHBY)/AbbVie's (ABBV) cancer drugs
- PR Newswire•2 days ago
Lilly to Participate in UBS Global Healthcare Conference
INDIANAPOLIS , May 16, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) will attend the UBS Global Healthcare Conference on Tuesday, May 21, 2019 . Christi Shaw , president of Lilly Bio-Medicines, ...
- Zacks•3 days ago
Pfizer's Eczema Candidate Meets All Goals in Phase III Study
Pfizer's (PFE) investigational eczema treatment abrocitinib succeeds in pivotal late-stage study.
- PR Newswire•3 days ago
Data Presentations at ASCO 2019 Highlight Lilly's Targeted Approach to Developing Treatments for Patients Living with Cancer
Lung cancer highlights to include the first presentation of RELAY results and additional findings from KEYNOTE-189 Lilly to share data from Phase 3 ANNOUNCE trial in people with advanced soft tissue sarcoma ...
- Motley Fool•4 days ago
3 Stocks With Big News Coming at ASCO 2019
These cancer drug developers could report market-moving news soon.
- Zacks•4 days ago
The Zacks Analyst Blog Highlights: Alphabet, Eli Lilly, CVS, Marriott and TELUS
The Zacks Analyst Blog Highlights: Alphabet, Eli Lilly, CVS, Marriott and TELUS
- Motley Fool•4 days ago
3 Top Diabetes Stocks to Watch in May
These three diabetes stocks should be on your radar right now.
- PR Newswire•4 days ago
Lilly to Participate in Bank of America Merrill Lynch Health Care Conference
INDIANAPOLIS , May 15, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will participate in the Bank of America Merrill Lynch 2019 Health Care Conference on Wednesday, May 15, 2019 . Enrique Conterno ...
- Zacks•4 days ago
Top Research Reports for Alphabet, Eli Lilly & CVS Health
Top Research Reports for Alphabet, Eli Lilly & CVS Health
- Zacks•5 days ago
Lilly's Cyramza Gets FDA Nod for Second-Line Liver Cancer
Lilly's (LLY) Cyramza gets FDA approval to treat AFP-high hepatocellular carcinoma (HCC), a common form of liver cancer. FDA removes boxed warning from label.
- PR Newswire•6 days ago
Lilly's CYRAMZA® (ramucirumab) Becomes First FDA-Approved Biomarker-Driven Therapy in Patients with Hepatocellular Carcinoma
This new indication - the fifth FDA approval for CYRAMZA in an advanced or metastatic cancer - is for the second-line treatment of patients with hepatocellular carcinoma (HCC) who are AFP-High (AFP ≥400 ...
- Reuters•8 days ago
Lilly's new migraine drug pulls ahead of Amgen in fierce battle for new prescriptions
Eli Lilly and Co has pulled ahead in a three-way race with Amgen Inc and Teva Pharmaceutical Industries Ltd in attracting new patients to a new class of migraine drugs, and seeks to build on that advantage by stressing that its therapy can completely prevent headaches in a small percentage of patients. Weekly U.S. prescription data from IQVIA, an analytics provider to the life sciences industry, showed that Lilly’s therapy Emgality claimed the largest share of first-time patients at 37.7 percent, for the first time outstripping Amgen’s Aimovig, whose share dropped to 37.2 percent as of April 26. Teva came in at a 25.1 percent share, according to an analyst who reviewed the data.
- Zacks•9 days ago
Radius (RDUS) Posts Narrower Q1 Loss, Misses on Revenues
Radius Health (RDUS) posts narrower-than-expected Q1 loss but Tymlos sales disappoint.
Associated Press•10 days agoTV pitches for prescription drugs will have to include price
WASHINGTON (AP) — TV pitches for prescription drugs will soon include the price, giving consumers more information upfront as they make medication choices at a time when new drugs can carry anxiety-inducing prices.
- PR Newswire•11 days ago
AAN 2019: Two New Analyses of Lasmiditan Phase 3 Studies Measured Onset of Effect and the Effect of Lasmiditan in Patients with Prior Triptan Experience
INDIANAPOLIS, May 8, 2019 /PRNewswire/ -- Eli Lilly and Company (LLY) today announced new data and post-hoc analyses for lasmiditan, an investigational, oral, first-in-class molecule for the acute treatment of migraine, being presented at the Annual Meeting of the American Academy of Neurology (AAN) taking place in Philadelphia from May 4-10, 2019. The presentations include pooled analyses from the Phase 3 SAMURAI and SPARTAN studies. The first analysis, presented on Monday, May 6, reviewed data on the early onset of effect of lasmiditan for several key outcomes.
- Zacks•12 days ago
Allergan (AGN) Beats on Q1 Earnings & Sales, Raises '19 View
Allergan's (AGN) stock declines slightly in pre-market trading despite the company delivering earnings and revenue beat in the first quarter while marginally raising its guidance
- Markit•12 days ago
See what the IHS Markit Score report has to say about Eli Lilly and Co.
Eli Lilly and Co NYSE:LLYView full report here! Summary * Perception of the company's creditworthiness is negative * ETFs holding this stock are seeing positive inflows but are weakening * Bearish sentiment is low * Economic output in this company's sector is expanding Bearish sentimentShort interest | PositiveShort interest is extremely low for LLY with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting LLY. Money flowETF/Index ownership | NegativeETF activity is negative and may be weakening. The net inflows of $3.81 billion over the last one-month into ETFs that hold LLY are among the lowest of the last year and appear to be slowing. Economic sentimentPMI by IHS Markit | PositiveAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, and is accelerating. Credit worthinessCredit default swap | NegativeThe current level displays a negative indicator. LLY credit default swap spreads are near their highest levels for the past 1 year, which indicates the market's more negative perception of the company's credit worthiness.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
- PR Newswire•13 days ago
Lilly Declares Second-Quarter 2019 Dividend
INDIANAPOLIS , May 6, 2019 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the second quarter of 2019 of $0.645 per share on outstanding common stock. ...
- Investor's Business Daily•13 days ago
Which Pharmaceutical Stocks Are Outperforming All Other Stocks?
The best pharmaceutical stocks to buy have commonalities: Strong Composite Ratings and Relative Strength Ratings.
- PR Newswire•13 days ago
AAN 2019: Pooled Analyses of Two Emgality® (galcanezumab-gnlm) Phase 3 Studies Show Reduction in Monthly Migraine Headache Days in Low- and High-Frequency Episodic Migraine Subgroups
INDIANAPOLIS , May 6, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the upcoming presentation of results from pooled subgroup analyses of efficacy data from the Phase 3 EVOLVE-1 ...
- Thomson Reuters StreetEvents•13 days ago
Edited Transcript of LLY earnings conference call or presentation 30-Apr-19 1:00pm GMT
Q1 2019 Eli Lilly and Co Earnings Call
